scholarly journals Hepatitis C Coinfection and Mortality in People Living with HIV in Middle Tennessee

2020 ◽  
Vol 36 (3) ◽  
pp. 193-199 ◽  
Author(s):  
Toni Hall ◽  
Cathy A. Jenkins ◽  
Todd Hulgan ◽  
Sally Furukawa ◽  
Megan Turner ◽  
...  
Keyword(s):  
Hepatitis C ◽  
People Living With Hiv ◽  
Middle Tennessee ◽  
Living With Hiv

scholarly journals Hepatitis C virus or hepatitis B virus coinfection and lymphoma risk in people living with HIV

AIDS ◽  
2020 ◽  
Vol 34 (4) ◽  
pp. 599-608 ◽  
Author(s):  
Caroline Besson ◽  
Nicolas Noel ◽  
Remi Lancar ◽  
Sophie Prevot ◽  
Michele Algarte-Genin ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Hepatitis B Virus ◽  
Hepatitis B ◽  
People Living With Hiv ◽  
B Virus ◽  
Living With Hiv ◽  
Lymphoma Risk

scholarly journals 355. Barriers for Hepatitis C Elimination in HIV/HCV Coinfected Patients

2019 ◽  
Vol 6 (Supplement_2) ◽  
pp. S187-S187
Author(s):  
Joe Espinoza ◽  
Karen J Vigil ◽  
Ben Barnett
Keyword(s):  
Hepatitis C ◽  
Open Access ◽  
People Living With Hiv ◽  
Access To Treatment ◽  
Active Intervention ◽  
Key Stakeholders ◽  
Wide Availability ◽  
Direct Acting ◽  
Treatment Use ◽  
Living With Hiv

Abstract Background Approximately 30% of people living with HIV are co-infected with Hepatitis C virus (HCV). HIV/HCV coinfected patients have faster progression to liver fibrosis, cirrhosis, and increased mortality, compared with monoinfected patients. Therefore, treatment in this population is a priority. The objective of this study was to develop an active program to reach HIV/HCV co-infected patients, with the goal to eliminate Hepatitis C in our local HIV clinic. Methods Beginning in December 2016, our clinic received State funds to support open access to treat HIV/HCV patients with direct-acting antivirals (DAA). From December 2016 to May 2018, the process was based on primarily on physician referrals to treat HIV/HCV patients at our clinic, without an active intervention, and 50 patients were treated. Our active intervention during the second part was based on the identification of all untreated HIV/HCV patients and contacting them directly, to link them to care. Results A total of 462 HIV/HCV co-infected patients were identified who qualified for the state-sponsored treatment program. From June 1, 2018 to July 31, 2018, only 7 patients were linked to care and started on DAA. The four main identified reasons for not getting DAA therapy were: no show up to the clinic appointments, poor adherence to their HIV antiretroviral treatment, use of drugs and not able to be reached (figure). Although drug use was listed as one of the main reasons for not receiving DAA therapy, it was not the defining reason for most patients. A majority of the patients had more than one obstacle preventing them from coming in to be treated. Conclusion Wide availability of DAA and open access to treatment is not enough to eliminate HIV/HCV co-infection. Innovative outreach processes with the active participation of key stakeholders are needed in order to eliminate this viral infection. Disclosures All authors: No reported disclosures.

scholarly journals Hepatitis B and hepatitis C prevalence among people living with HIV/AIDS in China: a systematic review and Meta-analysis

2020 ◽  
Vol 17 (1) ◽  
Author(s):  
Songxia Yu ◽  
Chengbo Yu ◽  
Jian Li ◽  
Shiming Liu ◽  
Haowen Wang ◽  
...  
Keyword(s):  
Systematic Review ◽  
Hepatitis C ◽  
Hepatitis B ◽  
Meta Analysis ◽  
People Living With Hiv ◽  
Living With Hiv ◽  
Hiv Aids

scholarly journals Low hepatitis C virus reinfection rate despite ongoing risk following universal access to direct-acting antiviral therapy among people living with HIV

AIDS ◽  
2020 ◽  
Vol 34 (9) ◽  
pp. 1347-1358
Author(s):  
Samira Hosseini-Hooshyar ◽  
Marianne Martinello ◽  
Jasmine Yee ◽  
Phillip Read ◽  
David Baker ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Antiviral Therapy ◽  
Universal Access ◽  
People Living With Hiv ◽  
Reinfection Rate ◽  
Direct Acting Antiviral ◽  
Direct Acting ◽  
Living With Hiv

scholarly journals The role of barriers to care on the propensity for hepatitis C virus nonreferral among people living with HIV

AIDS ◽  
2020 ◽  
Vol 34 (11) ◽  
pp. 1681-1683
Author(s):  
Edward R. Cachay ◽  
Francesca J. Torriani ◽  
Lucas Hill ◽  
Sonia Jain ◽  
Azucena Del Real ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Barriers To Care ◽  
People Living With Hiv ◽  
Living With Hiv

scholarly journals Association between chronic hepatitis C virus infection and myocardial infarction in people living with HIV in the United States

2018 ◽  
Author(s):  
Jessica Williams-Nguyen ◽  
Stephen E Hawes ◽  
Robin M Nance ◽  
Sara Lindström ◽  
Susan R Heckbert ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
The United States ◽  
Hcv Rna ◽  
High Risk Population ◽  
People Living With Hiv ◽  
Extrahepatic Manifestations ◽  
Chronic Hcv ◽  
Living With Hiv

AbstractHepatitis C virus (HCV) is common among people living with HIV (PLWH). The potential for extrahepatic manifestations of HCV, including myocardial infarction (MI), is a topic of active research. MI is classified into types, predominantly atheroembolic Type 1 MI (T1MI) and supply-demand mismatch Type 2 MI (T2MI). We examined the association between HCV and MI in the CFAR Network of Integrated Clinical Systems (CNICS), a multi-center clinical cohort of PLWH. MIs were centrally adjudicated and categorized by type using the Universal MI definition. We estimated the association between chronic HCV (RNA+) and time to MI adjusting for demographic characteristics, cardiovascular risk factors, clinical characteristics and substance use. Among 24,755 PLWH aged ≥18, there were 336 T1MI and 330 T2MI during a median of 4.2 years of follow-up. HCV was associated with a 68% greater risk of T2MI (adjusted hazard ratio (aHR) 1.68, 95% CI: 1.22, 2.30) but not T1MI (aHR 0.96, 95% CI: 0.63, 1.45). In a cause-specific analysis of T2MI, HCV was associated with a 2-fold greater risk of T2MI attributed to sepsis (aHR 2.26, 95% CI: 1.34, 3.81). Extrahepatic manifestations of HCV in this high-risk population are an important area for continued research.

Sign in / Sign up

Export Citation Format

Share Document